Alex Vieira Solves Debate on Best COVID19 Vaccine Making $1 Billion Dollar Call Betting on Moderna vs. Pfizer
With the help of the legend Alex Vieira, Intuitive Code published an invaluable extensive research report comparing COVID19 vaccines and an investment study comparing Moderna, Pfizer, and Gilead Sciences proven to be worth $1 billion to professional investors.
With the help of the legend Alex Vieira, Intuitive Code published an invaluable extensive research report comparing COVID19 vaccines and an investment study comparing Moderna, Pfizer, and Gilead Sciences, proven to be worth $1 billion to professional investors.
Firstly and foremost, this study came out before other vaccines became available. The report's aim, including a PDF and a 20-minutes video, was to inform investors that the only stock to buy long-term.
Gilead Sciences (GILD)
We downgraded Gilead Sciences (GILD) to Strong Sell, referring to the name as a Donald Trump Fraud. We made the downgrade available on the autonomous trading blog ahead of the share price crash.
Pfizer (PFE)
We initiated Pfizer (PFE) coverage with a neutral rating, informing investors that it was not worth investing in the company for reasons we cannot disclose publicly.
Invest in Moderna (MRNA)
We chose Moderna since the beginning as the only one worth investing in maintaining a strong buy rating. In addition, we urged full leverage investing in Moderna, having the highest price target worldwide.
A few months ago, we published a second research report after Moderna's share price plunged to $115, informing investors that were their last chance to buy more shares before seeing new all-time highs.
We sold over 8,000 copies of these studies to investors worldwide for $750, each helping them to succeed, a fact that we are very proud about.
We continue following up with them.
Market Proves Alex Vieira's Vaccine Stocks Study the Most Valuable
The stock market proved that Autonomous Trading research analysis - a complete study comparing vaccine stocks and the companies Moderna, Pfizer, and Gilead Sciences was the only viable alternative to investors.